Zacks Research Has Pessimistic Outlook of Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Zacks Research cut their Q2 2025 earnings estimates for shares of Biogen in a research note issued on Thursday, May 15th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will post earnings of $4.09 per share for the quarter, down from their previous forecast of $4.19. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen's Q3 2025 earnings at $3.85 EPS, Q4 2025 earnings at $3.67 EPS, FY2025 earnings at $14.64 EPS, Q1 2026 earnings at $3.42 EPS, Q3 2026 earnings at $3.74 EPS and Q4 2026 earnings at $3.68 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing the consensus estimate of $3.26 by ($0.24). The firm had revenue of $2.43 billion for the quarter, compared to analysts' expectations of $2.25 billion. Biogen had a net margin of 16.87% and a return on equity of 14.98%. Biogen's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $3.67 earnings per share.

A number of other research firms have also recently issued reports on BIIB. Mizuho dropped their price target on shares of Biogen from $207.00 to $169.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Hsbc Global Res cut shares of Biogen from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. HC Wainwright dropped their price target on shares of Biogen from $241.00 to $187.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Canaccord Genuity Group dropped their price target on shares of Biogen from $265.00 to $220.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Finally, HSBC cut shares of Biogen from a "buy" rating to a "hold" rating and set a $118.00 price target on the stock. in a research note on Monday, April 28th. Twenty analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, Biogen has an average rating of "Hold" and an average target price of $191.30.

Biogen Price Performance

Biogen stock opened at $125.59 on Monday. The company's fifty day moving average price is $125.96 and its 200 day moving average price is $142.09. Biogen has a 1 year low of $110.04 and a 1 year high of $238.00. The stock has a market capitalization of $18.40 billion, a P/E ratio of 11.22, a P/E/G ratio of 1.51 and a beta of 0.12. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35.

Institutional Trading of Biogen

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Larson Financial Group LLC increased its stake in Biogen by 640.9% during the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 141 shares during the period. Lee Danner & Bass Inc. purchased a new stake in Biogen during the fourth quarter worth about $25,000. Opal Wealth Advisors LLC purchased a new stake in Biogen during the first quarter worth about $26,000. Vision Financial Markets LLC purchased a new stake in Biogen during the first quarter worth about $27,000. Finally, Greykasell Wealth Strategies Inc. purchased a new stake in Biogen during the first quarter worth about $27,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the sale, the director now directly owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.